Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing

Sepideh Sadegh, Julian Matschinske, David B. Blumenthal, Gihanna Galindez, Tim Kacprowski, Markus List, Reza Nasirigerdeh, Mhaned Oubounyt, Andreas Pichlmair, Tim Daniel Rose, Marisol Salgado-Albarrán, Julian Späth, Alexey Stukalov, Nina K. Wenke, Kevin Yuan, Josch K. Pauling and Jan Baumbach ()
Additional contact information
Sepideh Sadegh: Technical University of Munich
Julian Matschinske: Technical University of Munich
David B. Blumenthal: Technical University of Munich
Gihanna Galindez: Technical University of Munich
Tim Kacprowski: Technical University of Munich
Markus List: Technical University of Munich
Reza Nasirigerdeh: Technical University of Munich
Mhaned Oubounyt: Technical University of Munich
Andreas Pichlmair: Technical University of Munich
Tim Daniel Rose: Technical University of Munich
Marisol Salgado-Albarrán: Technical University of Munich
Julian Späth: Technical University of Munich
Alexey Stukalov: Technical University of Munich
Nina K. Wenke: Technical University of Munich
Kevin Yuan: Technical University of Munich
Josch K. Pauling: Technical University of Munich
Jan Baumbach: Technical University of Munich

Nature Communications, 2020, vol. 11, issue 1, 1-9

Abstract: Abstract Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Various studies exist about the molecular mechanisms of viral infection. However, such information is spread across many publications and it is very time-consuming to integrate, and exploit. We develop CoVex, an interactive online platform for SARS-CoV-2 host interactome exploration and drug (target) identification. CoVex integrates virus-human protein interactions, human protein-protein interactions, and drug-target interactions. It allows visual exploration of the virus-host interactome and implements systems medicine algorithms for network-based prediction of drug candidates. Thus, CoVex is a resource to understand molecular mechanisms of pathogenicity and to prioritize candidate therapeutics. We investigate recent hypotheses on a systems biology level to explore mechanistic virus life cycle drivers, and to extract drug repurposing candidates. CoVex renders COVID-19 drug research systems-medicine-ready by giving the scientific community direct access to network medicine algorithms. It is available at https://exbio.wzw.tum.de/covex/.

Date: 2020
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-17189-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17189-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-17189-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().